Dorothee Deuring

Austrian, born 1968

Dorothee Deuring is a corporate finance specialist, with deep knowledge of the banking, pharmaceutical, chemical and utilities sectors.

She has been elected in 2024 as member of the Supervisory Board of OMV Aktiengesellschaft (Austrian listed company, ATX) and is a non-executive member of the Board of Directors and Audit and Remuneration Committees of Elementis plc (UK listed company, FTSE 250) since 2017.

Former mandates include PolyPeptide AG (Swiss listed company, 2023-2024), Axpo Holding AG (Switzerland, 2017-2023), Lonza Group AG (Swiss SMI listed company, 2020-2022), Immofinanz AG (Austria, 2021-2022), Bilfinger SE (Germany, 2016-2021), Piqur Therapeutics AG (Switzerland, 2019-2021), Selecta Group AG (Switzerland, 2020) and Röchling SE & Co. KG (Germany, 2016-2019).

Between 2011 and 2014, Dorothee led the European Corporate Finance Advisory Group of UBS AG Wealth Management as Managing Director. Prior to UBS, she served the Investment Banking arm of Bank Sal. Oppenheim Jr & Cie as Managing Director and Head Healthcare M&A. In 2003, she had joined Roche Diagnostics as a Vice-Director of Business Development and served Roche Corporate Finance Development until 2007. Dorothee started her career at McKinsey & Company in Switzerland in 1997.

Dorothee holds a Master’s degree in Chemistry from Université Louis Pasteur, Strasbourg, and a Master of Business Administration from INSEAD, Fontainebleau.

Acknowledging the importance of ESG matters, Dorothee is also acting as the Board executive sponsor for ESG matters and is a member of the Nomination & ESG Committee